摘要海曲泊帕（海曲泊帕乙醇胺片）是一种新型的小分子、口服、非肽类血小板生成素受体激动剂（TPO-RA）。2021年6月海曲泊帕获得我国国家药品监督管理局（NMPA）批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发性免疫性血小板减少症（ITP）成年患者以及对免疫抑制治疗（IST）反应不佳的重型再生障碍性贫血（SAA）成年患者。为指导临床规范应用海曲泊帕，使患者最大限度获益，根据海曲泊帕的临床研究进展，结合国内外权威指南、共识及TPO-RA类药物的应用现状，中国临床肿瘤学会（CSCO）抗肿瘤药物治疗安全管理专家委员会组织多学科专家认真讨论、反复修改，制定了该指导原则，供临床医师参考。

abstractsHetrombopag (hetrombopag olamine) is a novel, small-molecule, oral, non-peptide thrombopoietin receptor agonist (TPO-RA). In June 2021, hetrombopag was approval by the National Medical Products Administration (NMPA) for the treatment of adult patients with chronic primary immune thrombocytopenia (ITP) who have had a poor response to corticosteroids or immunoglobulins and adult patients with severe aplastic anemia who have had an insufficient response to immune suppressive therapy. In order to guide the clinical standardized application of hetrombopag and maximize the benefits of patients, the Anti-Cancer Drugs Safety Management Committee of Chinese Society of Clinical Oncology (CSCO) organized multidisciplinary experts to finalize the guiding principles for the reference of clinicians based on serious discussion and repeated revision, according to the clinical research progress of hetrombopag, in combination with the authoritative guidelines, consensus and the application status of TPO-RA drugs at home and abroad.